[go: up one dir, main page]

SI1680128T1 - Mio-inozitol heksafosfat za topično uporabo - Google Patents

Mio-inozitol heksafosfat za topično uporabo

Info

Publication number
SI1680128T1
SI1680128T1 SI200430274T SI200430274T SI1680128T1 SI 1680128 T1 SI1680128 T1 SI 1680128T1 SI 200430274 T SI200430274 T SI 200430274T SI 200430274 T SI200430274 T SI 200430274T SI 1680128 T1 SI1680128 T1 SI 1680128T1
Authority
SI
Slovenia
Prior art keywords
myo
inositol hexaphosphate
topical use
development
treatment
Prior art date
Application number
SI200430274T
Other languages
English (en)
Inventor
Freixedas F Grases
Bestard J Perello
Amengual B Isern
Almirall R Prieto
Bauz A Costa
Original Assignee
Sanifit S L Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanifit S L Lab filed Critical Sanifit S L Lab
Publication of SI1680128T1 publication Critical patent/SI1680128T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI200430274T 2003-11-07 2004-11-03 Mio-inozitol heksafosfat za topično uporabo SI1680128T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200302600A ES2232302B1 (es) 2003-11-07 2003-11-07 Myo-inositol hexafosfato para uso topico.
PCT/IB2004/003588 WO2005044278A1 (en) 2003-11-07 2004-11-03 Myo-inositol hexaphosphate for topical use
EP04798764A EP1680128B1 (en) 2003-11-07 2004-11-03 Myo-inositol hexaphosphate for topical use

Publications (1)

Publication Number Publication Date
SI1680128T1 true SI1680128T1 (sl) 2007-08-31

Family

ID=34566008

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200430274T SI1680128T1 (sl) 2003-11-07 2004-11-03 Mio-inozitol heksafosfat za topično uporabo

Country Status (15)

Country Link
US (1) US20070066574A1 (sl)
EP (1) EP1680128B1 (sl)
JP (1) JP4786543B2 (sl)
AT (1) ATE353655T1 (sl)
BR (1) BRPI0415713A (sl)
CA (1) CA2544963C (sl)
CY (1) CY1106574T1 (sl)
DE (1) DE602004004817T2 (sl)
DK (1) DK1680128T3 (sl)
ES (2) ES2232302B1 (sl)
MX (1) MXPA06005043A (sl)
PL (1) PL1680128T3 (sl)
PT (1) PT1680128E (sl)
SI (1) SI1680128T1 (sl)
WO (1) WO2005044278A1 (sl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2828206B1 (fr) * 2001-08-03 2004-09-24 Centre Nat Rech Scient Utilisation d'inhibiteurs des lysyl oxydases pour la culture cellulaire et le genie tissulaire
WO2003092700A1 (en) * 2002-04-29 2003-11-13 Gmp Oxycell, Inc. Inositol pyrophosphates, and methods of use thereof
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
US7745423B2 (en) * 2004-07-06 2010-06-29 NormOxys, Inc Calcium/sodium salt of inositol tripyrophosphate as an allosteric effector of hemoglobin
US20060106000A1 (en) * 2004-07-06 2006-05-18 Claude Nicolau Use of inositol-tripyrophosphate in treating tumors and diseases
US20060258626A1 (en) * 2004-07-06 2006-11-16 Claude Nicolau Use of inositol-tripyrophosphate in treating tumors and diseases
WO2006102060A1 (en) * 2005-03-18 2006-09-28 Oxyplus, Inc. Calcium salt of myo-inositol 1,6:2,3:4,5 tripyrophosphate as an allosteric effector of hemoglobin
ES2272191B1 (es) * 2005-10-14 2008-04-01 Universitat De Les Illes Balears Utilizacion del fitato para el tratamiento del agua.
ES2280136B1 (es) * 2006-02-17 2008-08-16 Universitat De Les Illes Balears Asociacion a dosis fija de fitato y zinc.
ES2288126B2 (es) * 2006-06-01 2009-07-06 Universitat De Les Illes Balears Utilizacion de fitato como agente inhibidor de la disolucion de cristales de sales calcicas para la prevencion o tratamiento de la osteoporosis.
WO2008134082A1 (en) * 2007-05-01 2008-11-06 Oxyplus, Inc. Erythropoietin complementation or replacement
ES2332636B1 (es) * 2008-08-06 2011-02-10 Universitat De Les Illes Balears Composicion de liquido de dialisis.
US9364490B2 (en) 2013-03-15 2016-06-14 Laboratoris Sanifit, S.L. Use of derivatives containing C—O—P bonds in patients with kidney failure
ES2495666B1 (es) * 2013-03-15 2015-08-10 Laboratoris Sanifit, S.L. Uso de derivados con enlaces c-o-p en pacientes con fallo renal
DE102016013737A1 (de) 2016-11-17 2018-05-17 WindplusSonne GmbH Hexahydroxycyclohexanhexaphosphorsäureestersalze zur Behandlung von Kalzinose sowie diätische Lebensmittel mit Hexahydroxycyclohexanhexaphosphorsäureestersalzen als Zusatzstoffe
JP7758319B2 (ja) * 2018-03-15 2025-10-22 株式会社ラフィーネインターナショナル 骨外組織における骨形成関連因子又は石灰化関連因子の発現抑制剤
CN120168489A (zh) 2018-10-11 2025-06-20 萨尼菲特治疗有限公司 用于治疗异位钙化的肌醇磷酸酯类
JP2022521119A (ja) 2019-01-30 2022-04-06 サニフィット・セラピューティクス・ソシエダッド・アノニマ 組織の灌流の増加における使用のためのイノシトールリン酸化合物
EP3818983A1 (en) 2019-11-11 2021-05-12 Sanifit Therapeutics S.A. Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification
EP4015494A1 (en) 2020-12-15 2022-06-22 Sanifit Therapeutics S.A. Processes for the preparation of soluble salts of inositol phosphates
EP4036097A1 (en) 2021-01-29 2022-08-03 Sanifit Therapeutics S.A. Ip4-4,6 substituted derivative compounds
TW202412815A (zh) 2022-07-29 2024-04-01 西班牙商薩尼菲特治療公司 Ip5經取代化合物
CA3263498A1 (en) 2022-07-29 2024-02-01 Vifor (International) Ltd. IP4-4,6 SUBSTITUTED DERIVATIVE COMPOUNDS INTENDED FOR USE IN THE TREATMENT, INHIBITION OF PROGRESSION AND PREVENTION OF ECTOPIC CALCIFICATION
WO2025162971A1 (en) 2024-01-31 2025-08-07 Sanifit Therapeutics, S.A. Substituted ip5 compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3934002A (en) * 1972-06-30 1976-01-20 The Procter & Gamble Company Oral compositions for plaque, caries and calculus retardation with reduced staining tendencies
JPH01305033A (ja) * 1988-06-01 1989-12-08 Sanwa Kagaku Kenkyusho Co Ltd 循環改善剤及び循環改善機能性食品並びにし好品
US5082833A (en) * 1988-06-30 1992-01-21 Shamsuddin Abulkalam M Reduction of cell proliferation and enhancement of nk-cell activity
US5268176A (en) * 1991-07-22 1993-12-07 Avon Products, Inc. Method and compositions for the non-invasive treatment of telangiectasia
US5516801A (en) * 1992-08-21 1996-05-14 Scotia Holdings Plc Fatty acid treatment for ectopic calcium deposition
DE4444238A1 (de) * 1994-12-13 1996-06-20 Beiersdorf Ag Kosmetische oder dermatologische Wirkstoffkombinationen aus Zimtsäurederivaten und Flavonglycosiden
US6359194B1 (en) * 1995-02-10 2002-03-19 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of cardiovascular disease
US5536499A (en) * 1995-02-24 1996-07-16 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Cosmetic compositions for reducing or preventing signs of cellulite
US5821237A (en) * 1995-06-07 1998-10-13 The Procter & Gamble Company Compositions for visually improving skin
US5614511A (en) * 1996-03-11 1997-03-25 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Cosmetic compositions for treating itchy skin
JP3623430B2 (ja) * 2000-07-06 2005-02-23 築野ライスファインケミカルズ株式会社 抗酸化性組成物
JP2003238414A (ja) * 2001-12-13 2003-08-27 Sangaku Renkei Kiko Kyushu:Kk 医薬組成物
EP1327443A1 (en) * 2001-12-21 2003-07-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic or preventing agent for the diseases caused by a decrease in the expression level of the klotho protein

Also Published As

Publication number Publication date
WO2005044278A1 (en) 2005-05-19
CA2544963A1 (en) 2005-05-19
CY1106574T1 (el) 2012-01-25
EP1680128A1 (en) 2006-07-19
BRPI0415713A (pt) 2006-12-19
ES2232302A1 (es) 2005-05-16
MXPA06005043A (es) 2007-03-15
ATE353655T1 (de) 2007-03-15
DK1680128T3 (da) 2007-06-11
CA2544963C (en) 2010-03-30
PL1680128T3 (pl) 2007-07-31
DE602004004817D1 (de) 2007-03-29
PT1680128E (pt) 2007-05-31
JP2007510710A (ja) 2007-04-26
DE602004004817T2 (de) 2007-11-22
US20070066574A1 (en) 2007-03-22
EP1680128B1 (en) 2007-02-14
JP4786543B2 (ja) 2011-10-05
ES2282920T3 (es) 2007-10-16
ES2232302B1 (es) 2006-08-01

Similar Documents

Publication Publication Date Title
PL1680128T3 (pl) Heksafosforan mio-inozytolu do stosowania miejscowego
WO2009002867A3 (en) Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
ATE355065T1 (de) Therapeutische zusammensetzungen bestehend aus antihypotensiva und antiangiogenika
TW200605870A (en) Topical methadone compositions and methods for using the same
IL154888A (en) Aqueous Pharmaceutical Gel Preparation Containing At least One Vitamin D or One Vitamin D Analog At least One Corticosteroid
UA94734C2 (ru) ТЕРАПЕВТИЧЕСКОЕ АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С b-АМИЛОИДНЫМ ПЕПТИДОМ
NO20075323L (no) Ernaeringspreparat for HIV-pasienter
PL1986669T3 (pl) Zastosowanie Bifidobacterium longum do zapobiegania i leczenia zapalenia
CR9181A (es) Antiangiogenesis terapia de autoinmunidad de enfermedad en pacientes a quienes a fallado la terapia previa
WO2006119958A3 (en) Use of flibanserin in the treatment of chronic pain
DOP2006000057A (es) Composición farmaceútica para el tratamiento del cáncer
AR034900A1 (es) Uso de una cantidad eficaz de un inhibidor de pde4 y un agente anticolinergico, bien en forma combinada sola o por separado, composiciones farmaceuticas que los comprenden, metodo para prepararlas, y uso de una composicion que comprende una cantidad eficaz de un inhibidor de pde4, una cantidad efica
ECSP077843A (es) Tratamiento o prevención del prurito
EA200970353A1 (ru) Комбинированное лекарственное средство
TW200511999A (en) Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone
AR036321A1 (es) Metodo y formulacion farmaceutica para el tratamiento de la discinesia de aparicion tardia.
PT1220676E (pt) Prevencao do cancro colorrectal
ES2325291A1 (es) "uso de un extracto de silybum marianum"
PT1893237E (pt) Composição farmacêutica compreendendo um elastómero organopolissiloxano e um princípio activo solubilizado
EA200801890A1 (ru) Средство для лечения шума в ушах
BRPI0512316A (pt) métodos para prevenir ou atenuar uma ou mais complicações da hemorragia intracerebral e para prevenir ou atenuar uma ou mais complicações da ich em uma maioria de pacientes com ich, e, uso de um primeiro agente de coagulação
ATE357220T1 (de) Pharmazeutische zusammensetzung mit modifizierter freisetzung
CR8584A (es) Piperazinas derivadas de urea para el tratamiento de la endometrosis
ATE484288T1 (de) Pharmazeutische zusammensetzungen zur linderung von übermässig hohen zuckerspiegeln bei diabetikern
WO2006032053A3 (en) Methods of treating symptoms of multiple sclerosis using vitamin d and related compounds